Vertex Pharmaceuticals (VRTX) Competitors $473.96 -2.99 (-0.63%) As of 03:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VRTX vs. AMZN, AXSM, CRSP, GOOG, ISRG, MRNA, RGEN, ABBV, LLY, and PFEShould you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Amazon.com (AMZN), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Alphabet (GOOG), Intuitive Surgical (ISRG), Moderna (MRNA), Repligen (RGEN), AbbVie (ABBV), Eli Lilly and Company (LLY), and Pfizer (PFE). Vertex Pharmaceuticals vs. Its Competitors Amazon.com Axsome Therapeutics CRISPR Therapeutics Alphabet Intuitive Surgical Moderna Repligen AbbVie Eli Lilly and Company Pfizer Vertex Pharmaceuticals (NASDAQ:VRTX) and Amazon.com (NASDAQ:AMZN) are related large-cap companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations. Does the media refer more to VRTX or AMZN? In the previous week, Amazon.com had 242 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 281 mentions for Amazon.com and 39 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.26 beat Amazon.com's score of 0.99 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 35 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amazon.com 178 Very Positive mention(s) 46 Positive mention(s) 32 Neutral mention(s) 13 Negative mention(s) 1 Very Negative mention(s) Positive Is VRTX or AMZN more profitable? Amazon.com has a net margin of 10.14% compared to Vertex Pharmaceuticals' net margin of -8.91%. Amazon.com's return on equity of 24.14% beat Vertex Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vertex Pharmaceuticals-8.91% -3.36% -2.42% Amazon.com 10.14%24.14%10.90% Which has preferable valuation and earnings, VRTX or AMZN? Amazon.com has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amazon.com, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVertex Pharmaceuticals$11.02B11.04-$535.60M-$3.92-120.91Amazon.com$637.96B3.86$59.25B$6.1437.81 Do analysts recommend VRTX or AMZN? Vertex Pharmaceuticals currently has a consensus target price of $512.30, indicating a potential upside of 8.09%. Amazon.com has a consensus target price of $254.33, indicating a potential upside of 9.56%. Given Amazon.com's stronger consensus rating and higher possible upside, analysts clearly believe Amazon.com is more favorable than Vertex Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vertex Pharmaceuticals 0 Sell rating(s) 14 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.52Amazon.com 0 Sell rating(s) 2 Hold rating(s) 45 Buy rating(s) 2 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in VRTX or AMZN? 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.2% of Amazon.com shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 9.7% of Amazon.com shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, VRTX or AMZN? Vertex Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Amazon.com has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. SummaryAmazon.com beats Vertex Pharmaceuticals on 14 of the 17 factors compared between the two stocks. Get Vertex Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRTX vs. The Competition Export to ExcelMetricVertex PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$121.65B$3.06B$5.67B$9.50BDividend YieldN/A2.44%4.05%4.00%P/E Ratio-120.8520.8427.9420.01Price / Sales11.04248.48396.9482.92Price / CashN/A41.9636.1958.45Price / Book7.448.308.645.84Net Income-$535.60M-$55.19M$3.24B$258.42M7 Day Performance2.31%5.18%3.27%2.14%1 Month Performance5.26%17.74%10.83%12.25%1 Year Performance-3.43%7.17%35.16%21.11% Vertex Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRTXVertex Pharmaceuticals4.3254 of 5 stars$473.96-0.6%$512.30+8.1%-2.7%$121.65B$11.02B-120.856,100Positive NewsAMZNAmazon.com4.3106 of 5 stars$225.68+0.3%$249.42+10.5%+22.5%$2.40T$637.96B36.761,556,000Trending NewsUpcoming EarningsAnalyst ForecastInsider TradeAXSMAxsome Therapeutics4.7254 of 5 stars$112.27+3.0%$172.33+53.5%+24.2%$5.53B$385.69M-19.46380Analyst RevisionCRSPCRISPR Therapeutics1.7629 of 5 stars$56.40-0.7%$71.75+27.2%+19.1%$4.87B$37.31M-12.48460Analyst ForecastAnalyst RevisionGOOGAlphabet4.6951 of 5 stars$182.85+0.8%$207.13+13.3%+4.3%$2.22T$350.02B20.38190,200Trending NewsEarnings ReportAnalyst ForecastInsider TradeOptions VolumeAnalyst RevisionGap UpISRGIntuitive Surgical4.6985 of 5 stars$516.47+0.9%$592.86+14.8%+10.3%$185.11B$8.35B75.7315,638Trending NewsEarnings ReportAnalyst ForecastMRNAModerna4.2637 of 5 stars$32.88-2.3%$46.61+41.8%-71.4%$12.73B$3.24B-3.775,800Analyst ForecastRGENRepligen4.6173 of 5 stars$121.75-6.5%$170.75+40.3%-11.7%$6.84B$650.43M-270.551,778Upcoming EarningsAnalyst UpgradeAnalyst RevisionABBVAbbVie4.8912 of 5 stars$191.54-0.5%$211.29+10.3%+9.9%$338.33B$56.33B81.5055,000Positive NewsUpcoming EarningsLLYEli Lilly and Company4.9838 of 5 stars$799.51+0.8%$1,012.56+26.6%-9.2%$757.72B$49.00B65.0547,000Trending NewsPFEPfizer4.9792 of 5 stars$25.36-1.2%$28.55+12.6%-14.1%$144.15B$62.46B18.3781,000Positive News Related Companies and Tools Related Companies Amazon.com Alternatives Axsome Therapeutics Alternatives CRISPR Therapeutics Alternatives Alphabet Alternatives Intuitive Surgical Alternatives Moderna Alternatives Repligen Alternatives AbbVie Alternatives Eli Lilly and Company Alternatives Pfizer Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRTX) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
